Mencia Gomez Devargas, MD
Psychosomatic Medicine · Hollywood, FLNPI 1285891754
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 71.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $3,594 and has fallen 92.4% since, to $274 in 2025.
Across 57 payments — averaging $82.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- E.r. Squibb & Sons, L.L.C.$301
- Lundbeck LLC$232
- Sunovion Pharmaceuticals Inc.$177
- AbbVie$134
- Neurocrine Biosciences, Inc.$119
- plus $363 from 8 others
Across 23 payments — averaging $12,319 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$277K
- Boehringer Ingelheim RCV GmbH & Co KG$6K
What the payments were for
- Travel & lodging$2,67157%
- Food & beverage$2,00843%
- Education$301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $3,381 |
| E.r. Squibb & Sons, L.L.C. | 5 | $301 |
| Lundbeck LLC | 10 | $232 |
| Sunovion Pharmaceuticals Inc. | 10 | $177 |
| AbbVie(2 entities) | 7 | $134 |
| Neurocrine Biosciences, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 3 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Avanir Pharmaceuticals, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Alfasigma USA, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychosomatic medicine providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $172,199 |
| Lurasidone Hcl | 36 | $10,101 |
| Trazodone Hcl | 100 | $1,219 |
| Aripiprazole | 49 | $1,215 |
| Quetiapine Fumarate | 109 | $1,164 |
| Olanzapine | 48 | $1,062 |
| Risperidone | 71 | $983 |
| Escitalopram Oxalate | 101 | $903 |
| Clonazepam | 204 | $709 |
| Duloxetine Hcl | 32 | $703 |
| Divalproex Sodium | 46 | $700 |
| Bupropion XlBupropion Hcl | 54 | $690 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 33 | $668 |
| Lamotrigine | 60 | $644 |
| Methylphenidate Hcl | 29 | $553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $111 | $172,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other psychosomatic medicine in Hollywood
- Clara Alvarez VillalbaHallandale Beach$3K
- Hortensa ValeronMiami$2K
- Nancy ChiarelloAtlantic Beach$135
- Laura CsereTampa$72
- Dominique MusselmanMiami$49
- Constanza Martinez PinanezMiami$17
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.